The place of tumor necrosis factor alpha inhibitors in the treatment of rheumatoid arthritis patients: tactics in different variants of the disease
As the period of use of genetically engineered biologic drugs (GEBD) in clinical practice is growing, clinicians are faced with new questions: how to switch from one GEBD to another in case of primary or secondary inefficacy, intolerance to previous GEBD therapy; what should be done after low diseas...
Main Author: | N. V. Chichasova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2015-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/180 |
Similar Items
-
TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH COMBINED PATHOLOGY
by: D. I. Khusainova, et al.
Published: (2020-06-01) -
The prediction and long-term maintenance of low disease activity during therapy with disease modifying anti-inflammatory drugs for rheumatoid arthritis
by: E.L. Luchikhina
Published: (2014-05-01) -
The role of etanercept in the treatment of patients with severe rheumatoid arthritis
by: N. V. Chichasova
Published: (2013-12-01) -
EFFECT OF «TREAT-TO-TARGET» ANTIRHEUMATIC THERAPY ON DIASTOLIC DYSFUNCTION OF THE LEFT AND RIGHT VENTRICLES IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS DURING 18 MONTHS OF OBSERVATION
by: I. G. Kirillova, et al.
Published: (2015-09-01) -
Tofacitinib in baseline treatment of rheumatoid arthritis: own clinical experience
by: A. R. Babaeva, et al.
Published: (2016-12-01)